Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)

Autor:	E. Hamilton, J. Meisel, C. Alemany, B. Virginia, N. Lin, R. Wesolowski, G. Mathauda-Sahota, D. Makower, J. Lawrence, D. Faltaos, Z. Mitri, D. Sabanathan, D. Clark, T. Pluard, R. Hui, N. McCarthy, M. Patel
Rok vydání:	2022
Předmět:	Cancer Research Oncology
Zdroj:	European Journal of Cancer. 174:S36
ISSN:	0959-8049
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::050a159dc73c596e5e1c8abd6093fac7 https://doi.org/10.1016/s0959-8049(22)00896-6 Zobrazit plný text záznamu Full Text from ScienceDirect